Navigation Links
Lilly Announces Termination of AIR Insulin Program
Date:3/7/2008

des answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. P-LLY

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as competitive developments affecting current products; rate of sales growth of recently launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed products; other regulatory developments and government investigations; patent disputes and other litigation involving current and future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; changes in tax law; asset impairments and restructuring charges; acquisitions and business development transactions; and the impact of exchange rates. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K filed February 2008. The company undertakes no duty to update forward-looking statements.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... NEW YORK , March 3, 2015 ... that Jeffrey I.D. Lewis has joined the ... Practice, resident in the New York ... also handles trademark matters, as well as other intellectual ... registered patent attorney, Mr. Lewis represents both plaintiffs and ...
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... the scientific journal, Expert Opinion on Biological Therapy ... Dr. Zhenggang Zhang , at the Henry Ford ... that Thymosin beta 4 (TB4) has the capacity to ... hours or more post-injury, leading to neurological recovery in ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... condition of esophagus eliminated in 90 percent ... ... BARRX Medical, Inc., the,global technology leader for treating precancerous conditions of ... a,multi-center U.S. study were free of the highest-risk of Barrett,s,esophagus after ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced that ... Annual Global Healthcare Conference on,May 19, 2008 at 4:55 ... 2008 UBS,Global Generic and Specialty Pharmaceuticals Conference on Thursday, ... EDT). The presentations will,be web cast live and may ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... March 31, 2008., For the third quarter of ... $6,900,000 reported in the same period last fiscal,year. Product ... the,Company,s business units., Net revenue for the third ...
Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 2Escalon(R) Reports Third Quarter Fiscal 2008 Results 3Escalon(R) Reports Third Quarter Fiscal 2008 Results 4Escalon(R) Reports Third Quarter Fiscal 2008 Results 5Escalon(R) Reports Third Quarter Fiscal 2008 Results 6Escalon(R) Reports Third Quarter Fiscal 2008 Results 7Escalon(R) Reports Third Quarter Fiscal 2008 Results 8
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... It,s long been known that alcohol use in ... birth defects, but researchers who study fetal alcohol syndrome ... disorder, detecting it early, or effectively treating it, say ... the issue of Developmental Neuroscience , four first-year ...
... How do we begin to understand what early life was ... planet shifted from an oxygen-free and probably ice-covered realm to ... who decodes the early record of life on Earth has ... a significantly clearer picture of this dynamic environment. Alison Olcott ...
... , THE WOODLANDS, Texas , June 15 ... company focused on discovering breakthrough treatments for human disease, announced today ... clinical trial of LX4211 for patients with type 2 ... June 19 – 22, 2010 in San Diego, ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Delineating primary and secondary organic carbon in neoproterozoic glacial sediments 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 2Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 3Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 4Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences 5
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Beads Sterile plating in just seconds ... and potentially hazardous ethanol flaming, More uniform ... ready-to-use sterile packaging: dispenser bottle for spreading 100 ... Fastest and easiest way to spread cells ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... laboratories working in a regulated environment, ... pipette calibration software that automates gravimetric ... a framework that meets todays regulatory ... a secure solution that includes a ...
Biology Products: